Selexis CHO Cells in Suspension-1

Gene to GMP

With GENE to GMP™ in 9 Months, we can help you achieve faster time-to-market while helping you lower the manufacturing costs of your promising drug candidates.

In June 2017, JSR Life Sciences acquired Selexis as part of JSR’s commitment to offer industry partners best-in-class contract development manufacturing (CDMO) services. Selexis SA and KBI Biopharma, which was acquired by JSR in 2015, have joined forces to provide industry partners “GENE to GMP in 9 Months” — the most robust service offering for the biopharmaceutical industry.

With GENE to GMP in 9 months, we are committed to our partners’ satisfaction. By predictably getting cGMP material for your clinical study, we help you concentrate on the other critical components of your development program.